Blumberg v. Stroma Medical Corp. CA4/3

CourtCalifornia Court of Appeal
DecidedMay 14, 2025
DocketG062786
StatusUnpublished

This text of Blumberg v. Stroma Medical Corp. CA4/3 (Blumberg v. Stroma Medical Corp. CA4/3) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blumberg v. Stroma Medical Corp. CA4/3, (Cal. Ct. App. 2025).

Opinion

Filed 5/14/25 Blumberg v. Stroma Medical Corp. CA4/3

NOT TO BE PUBLISHED IN OFFICIAL REPORTS

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA FOURTH APPELLATE DISTRICT DIVISION THREE

SAMUEL BLUMBERG,

Plaintiff and Appellant, G062786

v. (Super. Ct. No. 30-2020- 01172565) STROMA MEDICAL CORPORATION et al., OPINION

Defendants and Appellants.

Appeal from a judgment of the Superior Court of Orange County, Kimberly A. Knill, Judge. Affirmed in part, reversed in part, and remanded. Law Offices of Paul P. Cheng & Associates and Paul P. Cheng for Plaintiff and Appellant. Grodsky, Olecki & Puritsky and Allen B. Grodsky for Defendants and Appellants. For a little more than four years, plaintiff Samuel Blumberg worked for defendant Stroma Medical Corporation (Stroma), first as a consultant and then as a full-time employee. His compensation consisted almost entirely of options to purchase Stroma stock. In addition, Blumberg loaned Stroma a total of $130,100, evidenced by five convertible notes (Notes). Each note provided it would automatically convert to Stroma stock upon the occurrence of a defined equity financing event. Blumberg ultimately left his job at Stroma, and the method of his departure angered Gregg Homer, Stroma’s chairman of the board and chief scientific officer. Although Blumberg exercised his options and the triggering financing event specified in the Notes occurred, Stroma did not issue Blumberg any stock. Blumberg sued Stroma and Homer for breach of contract and conversion.1 After a jury awarded Blumberg more than $2.4 million in damages, Stroma and Homer (collectively, Defendants) moved for a new trial and for judgment notwithstanding the verdict (JNOV). The trial court denied the JNOV motion as to the breach of contract claim but granted it as to the conversion claim. Both Blumberg and Stroma appealed. Blumberg appeals the order granting JNOV on the conversion claim. We reverse that order and the resulting judgment. Defendants appeal the order denying JNOV on the breach of contract claim regarding the Notes. We affirm that order.

Defendants also appeal the jury’s award of damages on the conversion claim and award of punitive damages. We agree the damages on

1 Blumberg also sued Douglas Daniels, Stroma’s CEO. The jury found in Daniel’s favor on Blumberg’s claims.

2 the conversion claim were unsupported by the evidence and reverse and remand that award in part. We affirm the punitive damages award. FACTS I. BLUMBERG’S STOCK OPTIONS In June 2012, Blumberg began working as a consultant for Stroma, a start-up medical device company developing a technology to change the color of people’s eyes from dark to light. Blumberg’s consultancy was governed by a written agreement (Consulting Agreement) specifying he would be paid for his work with an option to purchase 27,235 shares of Stroma stock, which would vest during the period of the Consulting Agreement. Between June 1, 2013 and September 30, 2016, the Consulting Agreement was amended six times. With each amendment, the amount of the stock option grant increased. In total, as compensation for his consulting work, Blumberg received an option to purchase 130,905 shares of Stroma’s common stock. By the terms of the Consulting Agreement, the option had a term of “10 years, subject to earlier expiration in the event of the termination of [Blumberg’s] services hereunder (provide [sic] that the term of the Option shall be no less than two years unless [Blumberg’s] services hereunder are terminated for cause).” The option also was subject to the terms of Stroma’s 2009 stock plan and standard form stock option agreement, which gave Blumberg only three months after the termination of his service to exercise the option. The only compensation Blumberg received for his work as a consultant with Stroma was the stock option grant. In October 2016, Blumberg changed from consultant to full-time employee. Under the terms of his written employment agreement

3 (Employment Agreement), Blumberg was compensated with an additional stock option for 25,941 shares, which would vest over the first 12 months of his employment. Blumberg also received a base salary of $18,000 per year and was eligible for incentive bonuses. The option provided for in the Employment Agreement had a term of “10 years, subject to earlier expiration in the event of the termination of your services.” Like the option in the Consulting Agreement, it also was subject to Stroma’s 2009 stock option plan, which gave Blumberg only three months after the termination of his service in which to exercise the option. Blumberg’s employment with Stroma ended in March 2017. Homer was unhappy with the manner of Blumberg’s departure, which Homer believed injured the company. The parties entered into a severance agreement on March 17, 2017 (Severance Agreement) that, among other things, specified Blumberg would “retain all stock options covering shares in [Stroma] and vested” as of March 7, 2017. The Severance Agreement did not specify any expiration date. Whether the exercise period was three months, two years, or ten years, Blumberg timely exercised both options. He testified he exercised the consulting option when he transitioned to an employee by executing and delivering the exercise agreement attached as an exhibit to Stroma’s 2009 stock plan. Blumberg also testified that, several days before the Severance Agreement was finalized, he spoke directly with Douglas Daniels, the CEO of Stroma, who signed a writing prepared by Blumberg, which asked that all his options be exercised and the exercise cost be paid out of the indebtedness Stroma owed Blumberg on the Notes. By the terms of the writing, Daniels agreed to the request when he signed it.

4 II. BLUMBERG LOANED MONEY TO STROMA THROUGH A SERIES OF CONVERTIBLE NOTES Between April 2013 and December 2016, Blumberg loaned $130,100 to Stroma through a series of five convertible notes (in the amounts of $50,000, $25,000, $15,000, $30,000, and $10,100). The Notes’ maturity dates ranged from October 24, 2017 to December 14, 2019. III. STROMA DID NOT ISSUE BLUMBERG ANY SHARES PURSUANT TO THE OPTIONS AND DID NOT REPAY THE NOTES

Blumberg believed any rights he had under the stock options would expire on March 6, 2019—two years after his last day of work at Stroma (the deadline set forth in the Consulting Agreement). So, on February 28, 2019, Blumberg sent an email to Daniels asking about the options. Stroma had not issued Blumberg any shares of stock and had neither repaid nor converted the four Notes that had come due by the date of the email. Five days later, on March 5, 2019, Blumberg sent another email to Daniels, again expressing his concern about the options. Blumberg also sent Daniels a text message and left four voicemail messages. Rather than responding to the substance of the communications, Daniels directed Homer to respond to Blumberg and, after the close of business on March 6, 2019, sent Blumberg a brief message directing him to communicate with Homer. More than a month later, Homer finally responded to Blumberg’s communications. Homer informed Blumberg he had lost any right to exercise the options by failing to comply with certain terms of the Severance Agreement and, further, denied Blumberg had ever submitted an executed exercise agreement. He concluded with the following: “As you know, I’m not

5 happy with the manner in which you handled your departure. It had a negative impact on the company and frustrated some of our key administrative and quality control activities.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pfeifer v. John Crane, Inc.
220 Cal. App. 4th 1270 (California Court of Appeal, 2013)
Erlich v. Menezes
981 P.2d 978 (California Supreme Court, 1999)
Haines v. Parra
193 Cal. App. 3d 1553 (California Court of Appeal, 1987)
Krusi v. Bear, Stearns & Co.
144 Cal. App. 3d 664 (California Court of Appeal, 1983)
Mears v. Crocker First National Bank
191 P.2d 501 (California Court of Appeal, 1948)
Wolf v. Walt Disney Pictures and Television
76 Cal. Rptr. 3d 585 (California Court of Appeal, 2008)
Robinson Helicopter Co., Inc. v. Dana Corp.
102 P.3d 268 (California Supreme Court, 2004)
Roby v. McKesson Corp.
219 P.3d 749 (California Supreme Court, 2009)
Sweatman v. Department of Veterans Affairs
18 P.3d 29 (California Supreme Court, 2001)
Bermudez v. Ciolek
237 Cal. App. 4th 1311 (California Court of Appeal, 2015)
JMR Construction Corp. v. Environmental Assessment & Remediation Management, Inc.
243 Cal. App. 4th 571 (California Court of Appeal, 2015)
Imperial Valley Land Co. v. Globe Grain & Milling Co.
202 P. 129 (California Supreme Court, 1921)
Voris v. Lampert
446 P.3d 284 (California Supreme Court, 2019)
Ralston v. Bank of California
44 P. 476 (California Supreme Court, 1896)
W. Heritage Ins. Co. v. Frances Todd, Inc.
245 Cal. Rptr. 3d 552 (California Court of Appeals, 5th District, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Blumberg v. Stroma Medical Corp. CA4/3, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blumberg-v-stroma-medical-corp-ca43-calctapp-2025.